TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Healthy Eating and Weight Self-Efficacy (HEWSE) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Consumer Nutrition Knowledge Scale (CoNKS) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Motivation for Dietary Self-Control Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy and Optimal Biologic Dose of study treatment, as measured by Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of subjects with undiagnosed hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thalassaemia severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differentiation of right from left septal manifest accessory pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change on Victorian Institute of Sport Assessment- Achilles Specific Questionnaire (VISA-A)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incident Rate of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Acute Exacerbation Requiring Hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Time in range (TIR) at 24 weeks of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in range (TIR) at 28 weeks of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in range (TIR) at 34 weeks of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AFEQT sum scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self-reported symptom level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of participants with at least 20% subcutaneous fat change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in blood pressure at 6-weeks postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in blood pressure at 12-months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in body weight at 6-weeks postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in body weight at 12-months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in Circulating Concentration of Tumor Necrosis Factor Alpha (TNFα)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Asthma-specific Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Episodes of Prescriptions of 3 or More Days of Prednisolone (or Similar)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: self-reported negative affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-reported positive affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Morphologic complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Set shifting
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Arm Swings Characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-CoV-2 antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Different subsets of immune cells (neutrophils, dendritic cells, B- and T- lymphocytes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physical Function using Oswestry disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intra-operative Endoscopic Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of patient's illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity and impact of insomnia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI Measured Neural Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients who decide to enroll in a mesothelioma medical study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of mesothelioma patients who remain in clinical trial until completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intraoperative total consumption of opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in back-specific activity limitations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent Change in the Snaith-Hamilton Pleasure Scale (SHAPS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concussion incident
Endpoint domain: Adverse events/effects
Primary endpoint: Volume of highly metabolic organs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced Number of Visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rebleeding rate after endoscopic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sympathetic activity (burst frequency and incidence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative hair thickness density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anagen/telogen ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Physician's Global Assessment of Psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue Severity Scale - FSS
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in functional mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Vesical pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction of finger joint contracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HBV viral loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laryngospasm ratio
Endpoint domain: Adverse events/effects
Primary endpoint: Validity of blood tests for gastric cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post-treatment stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants suitable for recruitment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Death censored graft loss
Endpoint domain: Mortality/survival
Primary endpoint: Decline in eGFR value over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Nutrition Behavior Scale
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Health Perceptions and Health Behaviors Scale in Children
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physical Activity Self-Efficacy Scale for Children
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of Patients Experiencing Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Clinician satisfaction of the usability of the VERABAND™
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Likelihood of clinical adoption of the VERABAND™
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Incremental area under the curve of postprandial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of time with sensed glucose between 70 - 180 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Side effect frequency and severity
Endpoint domain: Adverse events/effects
Primary endpoint: Symptoms of mitochondrial disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the Resistell Phenotech vs Kirby-Bauer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppuration on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants without grade 3 and 4 treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants able to achieve donor engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants who are able to have donor engraftment persist
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in the Remaining wound healing (RWA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: MISTELS peg transfer task score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUTT assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease the loss of peripheral BCA rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area of FAZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Somatization symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of symptomatic, recurrent VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Clinically meaningful persistent post-surgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of Effective Parenting Test (KEPT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean duration of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in NICD1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Related Quality of Life (SF12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvements in Global longitudinal strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Histological Clearance of Target Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free Water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about HPV
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Effectiveness of Intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in First Step Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximum FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum estrogen (E1 and E2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Difference in Cmax between CYP2D6 and CYP2C19 phenotype groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in AUC0-n between CYP2D6 and CYP2C19 phenotype groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in AUC0-∞ between CYP2D6 and CYP2C19 phenotype groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in UL motor function on the Fugl-Meyer Stroke Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in UL functional performance on the Wolf Motor Function Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in motor cortex excitability by means of resting MEP amplitudes elicited by TMS over both hemispheres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain blood flow measured using Transcranial Doppler ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain blood flow measured using MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeding scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Favourable Outcome (mRS 0-1)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of high density lipoproteins levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional Ambulation Categories
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: percent screened subjects who enroll
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: percent enrolled subjects who complete
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percent adverse events, if any
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline of EORTC global health scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: accuracy of the planned intervention and clip placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Judgment Competence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area under the concentration-time curve (AUC[0-infinity]) of gepotidacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC[0-t] of gepotidacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of gepotidacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of lymphoedema-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of volume of the lower limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of successful manufacturing product (B7-H3CART) that met minimum assigned dose level range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) or Recommended phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral microorganism proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in detection rate for hazards
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with NG, CT, or early syphilis infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes From Baseline in Pulmonary Function Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes in Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proximal contacts tightness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Numerical Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Circulating tumor DNA kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: clinically significant changes in clinical laboratory safety tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degeneration of the L5-S1 disc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Score of Revised Child Anxiety and Depression Scale (RCADS-25)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in pain on the Visual analogue scale (VAS-10cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in disability on the Neck Disability Index (NDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neck range of motion measured through Goniometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative Tremor Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median COMI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dynamic sportive activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static sportive activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline body composition at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline bone microarchitecture at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline muscle strength at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline blood biomarkers at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusion Independence for at Least 12 Consecutive Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Measurement of PPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of AAVrh.10hFXN
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the Articular Cartilage Defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in Femoral Cartilage thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in the Pain Intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in Physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Perfusion Arterial Spin Labeling (ASL) fMRI Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in BOLD-related functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution of symptoms at the end of the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution of symptoms halfway through the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes